Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

View Full Paper
Ask AI
Bookmark
Share

Authors

HBH. BurtonLBLeora BoussiDNDavid Nemirovsky

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows outpatient cytarabine reduces hospitalization days in acute myeloid leukemia, indicating potential cost savings.

Key Points

  • Outpatient cytarabine reduced hospitalization days per cycle from 7.5 to 0.8, enhancing quality of life.
  • Cost per cycle for outpatient treatment was significantly lower at $14,244 versus $36,688 for inpatient care.
  • Retrospective cohort study included 198 adult patients with acute myeloid leukemia and compared outcomes.
  • Outpatient administration showed no impact on relapse-free or overall survival rates, suggesting safety of the approach.

Cite This Study

Burton et al. (2025) studied this question.

synapsesocial.com/papers/689fc948e46e096235ce14bdhttps://doi.org/10.1002/cncr.70024
View Full Paper
Ask AI
Bookmark
Share